Objectives

1. Review the approach to pharmacotherapy for T2DM (2020 guidelines update)

2. To discuss priorities in choosing the most appropriate DM medication for our patient: real life cases!

3.  Clinical pearls and practical aspects in prescribing SGLT2 inhibitors and GLP1 receptor agonists

Speaker

Sue D. Pedersen, MD, FRCPC
Specialist in Endocrinology & Metabolism                       

Diplomate, American Board of Obesity Medicine

C-ENDO Diabetes & Endocrinology Clinic

Calgary, AB, Canada

www.drsue.ca

Message from Dr Pedersen

I am excited to have you join us for an interactive, informative, practical discussion on the management of type 2 diabetes!  You can look forward to real-life case discussions, where we will (with your polling question help!) walk through the best approach to treatment.  Cases will range from the more straightforward patient, to the very complex. Should we reduce medication if the A1C is 5.8%? If a patient is a candidate for both SGLT2 inhibitor and GLP1 receptor agonist, what should we do?  Find out these answers and more at our event! I look forward to ‘seeing’ you there!

Sponsors

Clinical Science Liasion – Diabetes
AstraZeneca Canada
Rahiem El Borai, H.BSc, M.BT

Registration

Link https://astrazeneca.zoom.us/j/91961321737?pwd=ZnNuTldCVEs5Nmh3NVBZVloyYStrQT09

Please email education@albertanps.com to confirm your attendance